New KUBio Box For Viral Vectors Boosts Gene Therapy Manufacturing

Marlborough, MA - GE Healthcare Life Sciences is launching KUBio™ box, a fully-integrated, flexible, and adaptable biomanufacturing environment to accelerate the production of viral vector-based gene therapies. The latest addition to the KUBio modular bioprocessing portfolio, KUBio box is expected to speed gene therapies to market and contribute to increased capacity in the viral vector area.

Gene therapies are on the rise in the treatment of a wide range of diseases including cancer. Growing at a compound annual growth rate (CAGR) of 33.3% from 2017 to 2023, the gene therapy market is projected to reach $4.4 billion by 2023¹. With more than 700 cell and gene therapies currently in clinical trials, demand exceeds supply of viral vectors, used in approximately 70% of these therapies under trial. Current market indicators predict that the viral vector manufacturing market will hit $816 million by 2023².